Astrazeneca (AZN) said Wednesday its phase III trial for experimental therapy, anselamimab, in patients with advanced light chain amyloidosis did not meet its primary endpoint compared to placebo.
The company said the trial's main goal was a hierarchical combination of time to all-cause mortality and frequency of cardiovascular hospitalizations.
Despite missing the primary goal, the company said anselamimab significantly reduced death and hospitalizations in a prespecified patient subgroup.
Light chain amyloidosis is a rare disease characterized by the accumulation of misfolded proteins in organs, particularly the heart and kidneys.
Shares of the company fell nearly 1% to $69.7 in Wednesday's premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.